NVAX240726P18000
- 3.75
- 0.000.00%
Novavax Newsroom
Looking Into Novavax's Recent Short Interest
10 Health Care Stocks Whale Activity In Today's Session
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Express News | Novavax Inc : Jefferies Cuts Target Price to $31 From $38
Jefferies Maintains Novavax(NVAX.US) With Buy Rating, Cuts Target Price to $31
Novavax's Promising Outlook: Strong Market Positioning and Strategic Partnerships Fuel Buy Rating
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Here's How Much $100 Invested In Novavax 5 Years Ago Would Be Worth Today
Individual Investors Who Hold 46% of Novavax, Inc. (NASDAQ:NVAX) Gained 33%, Institutions Profited as Well
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Novavax, Inc. (NVAX) Is Attracting Investor Attention: Here Is What You Should Know
Novavax Options Spot-On: On July 15th, 69,528 Contracts Were Traded, With 392.8K Open Interest
What's Going On With Novavax Shares Monday?
Wall Street Bulls Look Optimistic About Novavax (NVAX): Should You Buy?
Does Novavax's (NASDAQ:NVAX) Pullback Could Signal a Buying Opportunity
Express News | State Street Corp Reports 4.32% Passive Stake in Novavax Inc as of June 30, 2024 Vs 12.11% as of April 30, 2023 - SEC Filing
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
Investors Push Novavax (NASDAQ:NVAX) 6.0% Lower This Week, Company's Increasing Losses Might Be to Blame
After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?
In April of this year, Pfizer's (PFE.US) stock price fell to its lowest point since January 2013. As of the closing of July 1st, the stock has risen by about 11% since then; after falling to an 11-year low, Pfizer has been in a consolidation phase for several months. So, should you sell or buy Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag of the cooling of its COVID-19 product and pushing forward the development of non-COVID-19 drug businesses. Recently, the company announced positive results from trials of two cancer drugs, but also closed a gene therapy program, and its stock price continues to range. In a study, patients received Pfizer's Elrex